Valuation & Earnings
This table compares IMAC and its rivals revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| IMAC | $72,050.00 | -$9.42 million | -0.00 |
| IMAC Competitors | $20.40 billion | $279.54 million | -236.23 |
IMAC’s rivals have higher revenue and earnings than IMAC. IMAC is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Volatility and Risk
IMAC has a beta of 1.68, meaning that its share price is 68% more volatile than the S&P 500. Comparatively, IMAC’s rivals have a beta of 0.97, meaning that their average share price is 3% less volatile than the S&P 500.
Insider & Institutional Ownership
Profitability
This table compares IMAC and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| IMAC | N/A | N/A | -325.44% |
| IMAC Competitors | -5.85% | -152.33% | -0.72% |
Summary
IMAC rivals beat IMAC on 5 of the 9 factors compared.
IMAC Company Profile
IMAC Holdings, Inc. owns and manages innovative medical advancements and care regeneration centers, and backspace clinics in the United States. The company's outpatient medical clinics provide regenerative, orthopedic, and minimally invasive procedures and therapies to patients with sports injuries, ligament and tendon damage, and other related soft tissue conditions, as well as back, knee, and joint pains. It also provides medical treatments, regenerative, spinal decompression, chiropractic manipulation, and physical medicine and therapy. IMAC Holdings, Inc. was founded in 2000 and is headquartered in Franklin, Tennessee.
Receive News & Ratings for IMAC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMAC and related companies with MarketBeat.com's FREE daily email newsletter.
